Hologic Inc's Revenue in the fiscal year 2025 $ 3,363.90 millions
Hologic Inc's Revenue in the fiscal year 2024 $ 2,407.80 millions
Hologic Inc's Revenue in the fiscal year 2023 $ 2,276.50 millions
Hologic Inc's Revenue in the fiscal year 2022 $ 3,293.10 millions
Hologic Inc's Revenue in the fiscal year 2021 $ 5,277.60 millions
HOLX Revenue first quarter 2026 Y/Y Growth Comment
Hologic Inc achieved in the first quarter 2026, above Company average Revenue rise of 44.84% year on year, to $ 907.40 millions.
Looking into first quarter 2026 results within Medical Laboratories industry 5 other companies have achieved higher Revenue growth. While Hologic Inc' s Revenue jump of 44.84% ranks overall at the positon no. 614 in the first quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Hologic Inc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
174.37 %
2.44 %
-100 %
(Sep 27 2025)
HOLX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Hologic Inc disclosed fall in Revenue from the fourth quarter by -46.45% to $ 907.40 millions, from $ 1,694.50 millions achived in the previous reporting period.
But that's not important problem, as Hologic Inc's Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry Hologic Inc achieved highest sequential Revenue growth. While Hologic Inc's Revenue growth quarter on quarter, overall rank is 261.
In the I. Quarter 2026 Hologic Inc disclosed fall in Revenue from the fourth quarter by -46.45% to $ 907.40 millions, from $ 1,694.50 millions achived in the previous reporting period.
But that's not important problem, as Hologic Inc's Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry Hologic Inc achieved highest sequential Revenue growth. While Hologic Inc's Revenue growth quarter on quarter, overall rank is 261.
Hologic Inc's 12 Months Revenue Growth Year on Year
Hologic Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 12.61% year on year, to $ 3,645 millions if the fiscal year would have ended in Dec 27 2025. Hologic Inc's trailing twelve months Revenue growth was higher than company's average -1469.02% and higher than -7.16% growth in Sep 27 2025. But from twelve months ended Sep 27 2025 rise was beneth at 8.35 % from $3363.9 millions achieved in the period from Sep 27 2025 to Dec 28 2024. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -1469.02%.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 244, from total ranking in previous quarter at 2174.
Hologic Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 12.61% year on year, to $ 3,645 millions if the fiscal year would have ended in Dec 27 2025. Hologic Inc's trailing twelve months Revenue growth was higher than company's average -1469.02% and higher than -7.16% growth in Sep 27 2025. But from twelve months ended Sep 27 2025 rise was beneth at 8.35 % from $3363.9 millions achieved in the period from Sep 27 2025 to Dec 28 2024. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -1469.02%. The momentum is even more impressive from twelve months ended Sep 27 2025 exhibited at 8.35 % increase from $3363.9 millions in the period from Sep 27 2025 to Dec 28 2024.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 244, from total ranking in previous quarter at 2174.
About Hologic Inc Revenue Growth Rates (HOLX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
78.13%